Vasculitis Foundation

Early VF-Funded Study Paves Way for New ANCA Vasculitis Clinical Trial

More than a decade ago, Donna O’Dell Bunch, PhD, was co-investigator in a Vasculitis Foundation-funded trial that studied changes in B cells (white blood cells that form antibodies) in patients with ANCA-associated vasculitis, and the medical implications of those changes on the disease. The findings from that 2007 clinical trial,…...

Read more

FDA Approves Otezla®for the Treatment of Oral Ulcers in Behcet’s Disease

Celgene Corporation announced on July 19 that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only…...

Read more

VF Celebrates Vasculitis Awareness Month 2018

The Vasculitis Foundation, the world’s largest organization dedicated to providing advocacy, education and support for people with vasculitis, announces the launch of Vasculitis Awareness Month (May 2018), an annual effort to create global awareness of the disease that’s so rare that fewer than 200,000 new cases are diagnosed each year.…...

Read more

VF Funds $160,000 in New Research

The VF Board of Directors is pleased to announce it has selected three new research studies for funding in 2018.  The studies were chosen from a selection of 20 applications submitted by investigators world-wide.  Every year the VF receives proposals for very high-quality research from investigators who have a wealth…...

Read more

Nucala Approved for EGPA/CSS Treatment

GlaxoSmithKline (GSK) achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US December 13, 2017:  GSK announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known…...

Read more